Log In
Print
BCIQ
Print
Print this Print this
 

PF-06263507

  Manage Alerts
Collapse Summary General Information
Company Oxford BioMedica plc
DescriptionHumanized mAb against oncofetal antigen 5T4
Molecular Target Oncofetal antigen 5T4
Mechanism of Action 
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation

Partner

Pfizer Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today